Cholyl-iFluor® 647 conjugate

Ordering information

Price
Catalog Number
Unit Size
Quantity

Add to cart

Additional ordering information

Telephone	1-800-990-8053
Fax	1-800-609-2943
Email	sales@aatbio.com
International	See distributors
Bulk request	Inquire
Custom size	Inquire
Shipping	Standard overnight for United States, inquire for international

Physical properties

Molecular weight	1289.57
Solvent	DMSO

Spectral properties

Correction Factor (260 nm)	0.03
Correction Factor (280 nm)	0.03
Correction Factor (656 nm)	0.0793
Extinction coefficient (cm ^-1 M ^-1)	250000¹
Excitation (nm)	656
Emission (nm)	670
Quantum yield	0.25¹

Storage, safety and handling

H-phrase	H303, H313, H333
Hazard symbol	XN
Intended use	Research Use Only (RUO)
R-phrase	R20, R21, R22
Storage	Freeze (< -15 °C); Minimize light exposure
UNSPSC	12171501

Overview SDS Protocol

Calculators

Common stock solution preparation

Table 1. Volume of DMSO needed to reconstitute specific mass of Cholyl-iFluor® 647 conjugate to given concentration. Note that volume is only for preparing stock solution. Refer to sample experimental protocol for appropriate experimental/physiological buffers.

	0.1 mg	0.5 mg	1 mg	5 mg	10 mg
1 mM	77.545 µL	387.726 µL	775.452 µL	3.877 mL	7.755 mL
5 mM	15.509 µL	77.545 µL	155.09 µL	775.452 µL	1.551 mL
10 mM	7.755 µL	38.773 µL	77.545 µL	387.726 µL	775.452 µL

Molarity calculator

Enter any two values (mass, volume, concentration) to calculate the third.

Mass (Calculate)		Molecular weight		Volume (Calculate)		Concentration (Calculate)		Moles
	/		=		x		=

Spectrum

Open in Advanced Spectrum Viewer

Spectral properties

Correction Factor (260 nm)	0.03
Correction Factor (280 nm)	0.03
Correction Factor (656 nm)	0.0793
Extinction coefficient (cm ^-1 M ^-1)	250000¹
Excitation (nm)	656
Emission (nm)	670
Quantum yield	0.25¹

Product Family

Name	Excitation (nm)	Emission (nm)	Extinction coefficient (cm ^-1 M ^-1)	Quantum yield	Correction Factor (260 nm)	Correction Factor (280 nm)	Correction Factor (656 nm)
iFluor® 647-streptavidin conjugate	656	670	250000¹	0.25¹	0.03	0.03	0.0793
Phalloidin-iFluor® 647 Conjugate	656	670	250000¹	0.25¹	0.03	0.03	0.0793

Images

Figure 1. Chemical structure for Cholyl-iFluor® 647 conjugate.

References

View all 19 references: Citation Explorer

Novel hypolipidemic conjugates of fatty acid and bile acid with lysine for linkage.
Authors: Jin, Xue-Yuan and Zhu, Chuan-Bao and Fan, Shi-Yong and Sun, Jia-Lin and Shi, Yu-Cong and Wang, Chu-Han and Wang, Hui-Fen and Zhong, Bo-Hua and Yao, Yi-Shan and Shi, Wei-Guo
Journal: Drug development and industrial pharmacy (2019): 995-998

The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease.
Authors: Safadi, Rifaat and Konikoff, Fred M and Mahamid, Mahmud and Zelber-Sagi, Shira and Halpern, Maya and Gilat, Tuvia and Oren, Ran and ,
Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Associatio (2014): 2085-91.e1

L-arginine conjugates of bile acids-a possible treatment for non-alcoholic fatty liver disease.
Authors: Voloshin, Irina and Hahn-Obercyger, Michal and Anavi, Sarit and Tirosh, Oren
Journal: Lipids in health and disease (2014): 69

Amino acid-bile acid based molecules: extremely narrow surfactant nanotubes formed by a phenylalanine-substituted cholic acid.
Authors: Travaglini, Leana and D'Annibale, Andrea and Schillén, Karin and Olsson, Ulf and Sennato, Simona and Pavel, Nicolae V and Galantini, Luciano
Journal: Chemical communications (Cambridge, England) (2012): 12011-3

Fatty acid bile acid conjugate inhibits hepatic stearoyl coenzyme A desaturase and is non-atherogenic.
Authors: Leikin-Frenkel, Alicia and Gonen, Ayelet and Shaish, Aviv and Goldiner, Ilana and Leikin-Gobbi, Diana and Konikoff, Fred M and Harats, Dror and Gilat, Tuvia
Journal: Archives of medical research (2010): 397-404

Hypocholesterolemic effects of fatty acid bile acid conjugates (FABACs) in mice.
Authors: Leikin-Frenkel, Alicia and Parini, Paolo and Konikoff, Fred M and Benthin, Lisbet and Leikin-Gobbi, Diana and Goldiner, Ilana and Einarsson, Curt and Gilat, Tuvia
Journal: Archives of biochemistry and biophysics (2008): 63-71

Treatment of preestablished diet-induced fatty liver by oral fatty acid-bile acid conjugates in rodents.
Authors: Leikin-Frenkel, Alicia and Goldiner, Ilana and Leikin-Gobbi, Diana and Rosenberg, Ruth and Bonen, Hamutal and Litvak, Alex and Bernheim, Joelle and Konikoff, Fred M and Gilat, Tuvia
Journal: European journal of gastroenterology & hepatology (2008): 1205-13

[Innovations in the medical treatment of gallstones and fatty liver: FABACs (Fatty Acid Bile Acid Conjugates)].
Authors: Keizman, Daniel and Goldiner, Ilana and Leikin-Frenkel, Alicia and Konikoff, Fred M
Journal: Harefuah (2008): 344-9, 373, 372

New targets in and potential treatments for cholesterol gallstone disease.
Authors: Doggrell, Sheila A
Journal: Current opinion in investigational drugs (London, England : 2000) (2006): 344-8

ABCA1-dependent but apoA-I-independent cholesterol efflux mediated by fatty acid-bile acid conjugates (FABACs).
Authors: Goldiner, Ilana and van der Velde, Astrid E and Vandenberghe, Kristin E and van Wijland, Michel A and Halpern, Zamir and Gilat, Tuvia and Konikoff, Fred M and Veldman, Robert Jan and Groen, Albert K
Journal: The Biochemical journal (2006): 529-36